The research is led by infectious disease clinician George Sakoulas, M.D. of Sharp Memorial Hospital and the Sharp Rees-Stealy Medical Group in San Diego, Calif., and Associate Professor
The approval, which is based on results from the phase 3 BEACON CRC trial, enables to market Braftovi plus cetuximab in 27 EU member states, as well as
AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement. ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001
The regulator has provided the company with the permission to submit an investigational new drug application (IND) to use FSD-201 for the treatment of Covid-19, the disease resulted
As part of the sponsored collaboration research agreements, Codiak researchers will work with Bruce Walker, M.D., and Gaurav Gaiha, M.D., D.Phil., of the Ragon Institute to build integrated
The regulator has approved the company’s heart disease drug Brilinta based on positive data from the phase III THEMIS study. According to the company, the study demonstrated a
The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on
The REMDACTA is a two-armed global phase III, randomised, double-blind and multicentre study designed to assess the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir against
If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation. Treatment options are
The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.